These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 12947360)

  • 1. Metabolic syndrome and coronary angiographic disease progression: the Women's Angiographic Vitamin & Estrogen trial.
    Hsia J; Bittner V; Tripputi M; Howard BV
    Am Heart J; 2003 Sep; 146(3):439-45. PubMed ID: 12947360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cystatin C levels on angiographic atherosclerosis progression and events among postmenopausal women with angiographically decompensated coronary artery disease (from the Women's Angiographic Vitamin and Estrogen [WAVE] study).
    Patel D; Ahmad S; Silverman A; Lindsay J
    Am J Cardiol; 2013 Jun; 111(12):1681-7. PubMed ID: 23499273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of serum endothelin levels in predicting death and myocardial infarction but not coronary progression in postmenopausal women with coronary disease (from the Women's Angiographic Vitamin and Estrogen [WAVE] study).
    Ruo B; Tripputi MT; Hsue PY; Saigo M; Ouyang P; Waters DD
    Am J Cardiol; 2005 Aug; 96(3):335-8. PubMed ID: 16054453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remnant-like lipoproteins, hormone therapy, and angiographic and clinical outcomes: the Women's Angiographic Vitamin & Estrogen Trial.
    Bittner V; Tripputi M; Hsia J; Gupta H; Steffes M;
    Am Heart J; 2004 Aug; 148(2):293-9. PubMed ID: 15308999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries.
    Ouyang P; Tardif JC; Herrington DM; Stewart KJ; Thompson PD; Walsh MN; Bennett SK; Heldman AW; Tayback MA; Wang NY;
    Atherosclerosis; 2006 Dec; 189(2):375-86. PubMed ID: 16442114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes, the metabolic syndrome, and angiographic progression of coronary arterial disease in postmenopausal women.
    Mellen PB; Cefalu WT; Herrington DM
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):189-93. PubMed ID: 16239594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation.
    Marroquin OC; Kip KE; Kelley DE; Johnson BD; Shaw LJ; Bairey Merz CN; Sharaf BL; Pepine CJ; Sopko G; Reis SE;
    Circulation; 2004 Feb; 109(6):714-21. PubMed ID: 14970105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fasting plasma glucose predicts survival and angiographic progression in high-risk postmenopausal women with coronary artery disease.
    Vaidya D; Kelemen MD; Bittner V; Tardif JC; Thompson P; Ouyang P
    J Womens Health (Larchmt); 2007 Mar; 16(2):228-34. PubMed ID: 17388739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial.
    Kelemen M; Vaidya D; Waters DD; Howard BV; Cobb F; Younes N; Tripputti M; Ouyang P
    Atherosclerosis; 2005 Mar; 179(1):193-200. PubMed ID: 15721027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women.
    Wessel TR; Arant CB; Olson MB; Johnson BD; Reis SE; Sharaf BL; Shaw LJ; Handberg E; Sopko G; Kelsey SF; Pepine CJ; Merz NB
    JAMA; 2004 Sep; 292(10):1179-87. PubMed ID: 15353530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes exacerbates angiographic coronary lesion progression in subjects with metabolic syndrome independent of CRP levels.
    Liang KW; Lee WJ; Lee WL; Chen YT; Ting CT; Sheu WH
    Clin Chim Acta; 2008 Feb; 388(1-2):41-5. PubMed ID: 17967444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does prevalence of the metabolic syndrome in women with coronary artery disease differ by the ATP III and IDF criteria?
    Brown TM; Vaidya D; Rogers WJ; Waters DD; Howard BV; Tardif JC; Bittner V
    J Womens Health (Larchmt); 2008 Jun; 17(5):841-7. PubMed ID: 18537485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation.
    Merz CN; Johnson BD; Berga S; Braunstein G; Reis SE; Bittner V;
    Fertil Steril; 2006 May; 85(5):1425-31. PubMed ID: 16600235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of coronary calcification in healthy postmenopausal women.
    Hsia J; Klouj A; Prasad A; Burt J; Adams-Campbell LL; Howard BV
    BMC Cardiovasc Disord; 2004 Dec; 4():21. PubMed ID: 15574196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordant association of C-reactive protein with clinical events and coronary luminal narrowing in postmenopausal women: data from the Women's Angiographic Vitamin and Estrogen (WAVE) study.
    Patel D; Jhamnani S; Ahmad S; Silverman A; Lindsay J
    Clin Cardiol; 2013 Sep; 36(9):535-41. PubMed ID: 23754758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of quantitative computerized and human panel coronary endpoint measures: implications for the design of angiographic trials.
    Mack WJ; Azen SP; Dunn M; Hodis HN
    Control Clin Trials; 1997 Apr; 18(2):168-79. PubMed ID: 9129860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structured hypocaloric diet is more effective than behavioral therapy in reducing metabolic syndrome in Mexican postmenopausal women: a randomized controlled trial.
    Perichart-Perera O; Balas-Nakash M; Muñoz-Manrique C; Legorreta-Legorreta J; Rodríguez-Cano A; Mier-Cabrera J; Aguilera-Pérez JR
    Menopause; 2014 Jul; 21(7):711-20. PubMed ID: 24378762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.
    Schrott HG; Bittner V; Vittinghoff E; Herrington DM; Hulley S
    JAMA; 1997 Apr 23-30; 277(16):1281-6. PubMed ID: 9109465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study.
    Kip KE; Marroquin OC; Kelley DE; Johnson BD; Kelsey SF; Shaw LJ; Rogers WJ; Reis SE
    Circulation; 2004 Feb; 109(6):706-13. PubMed ID: 14970104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions.
    O'Brien JE; Peterson ED; Keeler GP; Berdan LG; Ohman EM; Faxon DP; Jacobs AK; Topol EJ; Califf RM
    J Am Coll Cardiol; 1996 Nov; 28(5):1111-8. PubMed ID: 8890803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.